In Recent Guidance, FDA aims for Patient Safety at 503B Facilities
The FDA has issued a guidance to 503B facilities regarding Current Good Manufacturing Practice (gCMB)
The FDA has issued a guidance to 503B facilities regarding Current Good Manufacturing Practice (gCMB)
At ConsortiEX, we work diligently to create solutions designed specifically for the unique needs of health system pharmacies. The result is our Assure-Trak® IV Workflow Management Dynamic Patient Specific Compounding application a dynamically configurable IV Workflow solution to enhance patient safety and optimize[...]
Just last week, ConsortiEX proudly announced our new InsightRX Passive Audit Monitoring module.
Today, cost and quality issues surrounding compounded sterile preparations (CSP’s) have nearly every major health system investigating what it takes to re-insource production. Most are looking at a hub and spoke approach, where their central-fill Batch Compounding can support the CSP production needs of all the[...]
ConsortiEX is proudly attending ASHP Midyear. Stop by Booth 900 to see how our intuitive Pharmacy-Focused ERP solutions can enhance your patient safety, ensure quality control, and simplify compliance, first-hand and in-person. Our new InsightRX Passive Audit Monitoring hood will be on display.
Introducing InsightRX Passive Audit Monitoring: See what others miss.
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency. We recognize that in delivering on implementation commitments, we must balance the need to preserve[...]
Office: (414) 231-4575
Support: (888) 434-1442
2020 | ConsortiEX Inc. | All Rights Reserved